Dan Leonard, National Pharmaceutical Council president and CEO, in a recent commentary published on Pharmacy Times outlines some areas where the Institute for Clinical and Economic Review (ICER) could improve its value assessment framework.
The NPC, Lenoard writes, submitted feedback to ICER as the organization looks to update its value assessment framework. Changes were suggested in the following areas:
- Changes to the core framework;
- Changes to the assessment procedure;
- Expanding the framework’s scope.
“Ultimately, it’s the patients who are affected most by value frameworks,” Lenoard writes. “Done well, such assessments can help guide patient access to high-value treatments. But done poorly, without fully taking the needs of patients into account, value assessments could be used as a mechanism that makes getting needed treatments harder.”
To read Lenoard’s full write up, click here.